Details of Disease

General Information of Disease (ID: DISHC0U7)

Disease Name Gout
Synonyms tophaceous disease; tophaceous gout; chronic gout; gouty arthritis; articular gout; gout; gouty arthropathy
Disease Class FA25: Gout
Definition A condition characterized by painful swelling of the joints, which is caused by deposition of urate crystals.
Disease Hierarchy
DIS71G5H: Metabolic disorder
DISHC0U7: Gout
ICD Code
ICD-11
ICD-11: FA25
ICD-10
ICD-10: M10
Expand ICD-11
'FA25
Expand ICD-10
'M10
Expand ICD-9
274.00274.1274.8274.9
Disease Identifiers
MONDO ID
MONDO_0005393
MESH ID
D006073
UMLS CUI
C0018099
MedGen ID
42280
HPO ID
HP:0001997
SNOMED CT ID
90560007

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 9 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Allopurinol DMLPAOB Approved Small molecular drug [1]
Benzbromarone DMC3YUA Approved Small molecular drug [2]
Colchicine DM2POTE Approved Small molecular drug [3]
Indomethacin DMSC4A7 Approved Small molecular drug [4]
Naproxen DMZ5RGV Approved Small molecular drug [5]
Pegloticase DMCLR6G Approved NA [6]
Probenecid DMMFWOJ Approved Small molecular drug [7]
Sodium thiosalicylate DMD7ANN Approved NA [2]
Sulfinpyrazone DMEV954 Approved Small molecular drug [8]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 Drug(s)
This Disease is Treated as An Indication in 18 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Dotinurad DM0UPQJ Phase 3 Small molecule [9]
esuberaprost DMXLGED Phase 3 Small molecular drug [10]
MBX-102 DMONYS9 Phase 2/3 Small molecular drug [11]
ALLN-346 DMZMG96 Phase 2 Enzyme replacement [12]
AR882 DMFGYZ8 Phase 2 Small molecule [13]
BCX-3408 DMRSG31 Phase 2 Small molecular drug [14]
DYV700 DMQTDD1 Phase 2 NA [15]
DYV702 DMOVXHR Phase 2 NA [15]
RDEA-684 DMNWYHD Phase 2 NA [16]
SAP-001 DM4DP70 Phase 2 NA [17]
SELA-212 DMOG4TF Phase 2 NA [18]
Topiroxostat DMA04DE Phase 2 Small molecular drug [19]
URC102 DMY89BN Phase 2 NA [20]
ALN-XDH DM9I6EO Phase 1/2 RNA interference [21]
LC-350189 DMHT3CB Phase 1 NA [22]
Oxeglitazar DMN4LMT Phase 1 Small molecular drug [23]
Pegadricase DMB5JWX Phase 1 NA [24]
PF-06743649 DMOLHKC Phase 1 NA [25]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 Drug(s)
This Disease is Treated as An Indication in 4 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
INDOPROFEN DM5QSKN Withdrawn from market Small molecular drug [2]
Ponalrestat DM04ZUW Discontinued in Phase 3 Small molecular drug [26]
BOF-4272 DMK0PVC Discontinued in Phase 2 Small molecular drug [27]
Y-700 DMHFTD0 Discontinued in Phase 2 Small molecular drug [28]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 5 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ALTU-242 DME0FMU Investigative NA [29]
Aom-0763 DML1PV3 Investigative NA [30]
APG-101.10 DMPPWJ4 Investigative NA [29]
IL1R1 NAM DMV50Y3 Investigative NA [29]
PN-2107 DM34LZ3 Investigative NA [29]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 35 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ABCA1 TTJW1GN Limited Genetic Variation [31]
ABCC8 TTP835K Limited Genetic Variation [31]
ABCC9 TTEF5MJ Limited Genetic Variation [31]
ABCG1 TTMWDGU Limited Genetic Variation [31]
ABCG2 TTIMJ02 Limited Genetic Variation [32]
ALDH2 TTFLN4T Limited Genetic Variation [33]
BDKRB2 TTGY8IW Limited Genetic Variation [31]
CD14 TT6I7DC Limited Biomarker [34]
CFTR TTRLZHP Limited Genetic Variation [31]
CYP2E1 TTWVHQ5 Limited Genetic Variation [31]
KCNQ1 TT846HF Limited Genetic Variation [35]
MAP3K11 TTETX6Q Limited Genetic Variation [36]
PDE1C TTW2HRK Limited Genetic Variation [31]
PPARD TT2JWF6 Limited Genetic Variation [31]
PRKCA TTFJ8Q1 Limited Genetic Variation [31]
RARB TTISP28 Limited Genetic Variation [31]
SLC22A1 TTM5Q4V Limited Genetic Variation [31]
SLC2A9 TTIF3GB Limited Genetic Variation [33]
VDR TTK59TV Limited Genetic Variation [31]
XDH TT7RJY8 Limited Biomarker [37]
ACVR2A TTX2DRI Strong Genetic Variation [38]
CD160 TTOFEAS Strong Genetic Variation [38]
HNF1A TT01M3K Strong Genetic Variation [38]
IL1RN TT6GSR3 Strong Therapeutic [39]
INSR TTCBFJO Strong Genetic Variation [38]
MAP4K2 TTQFRP0 Strong Genetic Variation [38]
MUC1 TTBHFYQ Strong Genetic Variation [38]
NRG4 TTWAGKJ Strong Genetic Variation [38]
PDZK1 TTDTBLM Strong Genetic Variation [38]
PRKG2 TTDWFCQ Strong Biomarker [40]
PYGM TTZHY6R Strong Genetic Variation [38]
SH2B3 TT36N7Z Strong Genetic Variation [38]
SLC22A12 TTA592U Strong Genetic Variation [38]
SLC40A1 TT6Y1PG Strong Biomarker [41]
SLC5A6 TT61XTV Strong Genetic Variation [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 35 DTT(s)
This Disease Is Related to 8 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC13A3 DTKXTPW Limited Genetic Variation [31]
SLC16A9 DTQK5O9 Limited Genetic Variation [42]
SLC17A1 DT8ARWJ Limited Genetic Variation [42]
SLC17A2 DTRF4L3 Strong Genetic Variation [38]
SLC17A3 DTFOJL7 Strong Genetic Variation [38]
SLC17A4 DTHE530 Strong Genetic Variation [38]
SLC22A11 DT06JWZ Strong Genetic Variation [38]
SLC22A7 DT0OC1Q Strong Genetic Variation [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DTP(s)
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
ALDH1A2 DEKN1H4 Limited Genetic Variation [31]
CYP2C8 DES5XRU Limited Genetic Variation [31]
HPRT1 DEVXTP5 Strong Genetic Variation [43]
------------------------------------------------------------------------------------
This Disease Is Related to 81 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ALX4 OTNS9A29 Limited Genetic Variation [31]
ATP1A4 OT9PLMBH Limited Genetic Variation [31]
BCAS3 OTDVAX6B Limited Genetic Variation [35]
CARD8 OTXXZYWU Limited Biomarker [44]
CNIH2 OTT2ECCW Limited Genetic Variation [45]
CNTN5 OTWU5FLZ Limited Genetic Variation [33]
CUX2 OTDJTQAJ Limited Genetic Variation [45]
FAM53A OT92WJE6 Limited Genetic Variation [33]
FSTL4 OTTNB9ZP Limited Genetic Variation [31]
GCKR OTSIWXGG Limited Genetic Variation [42]
JAZF1 OTXTYSYD Limited Genetic Variation [31]
LHFPL3 OTG1EI22 Limited Genetic Variation [31]
NIPAL1 OTRYI60X Limited Genetic Variation [45]
NRXN2 OTB04QSU Limited Genetic Variation [45]
PKD2 OTIXBU8H Limited Genetic Variation [46]
PTPRD OTZPJ3GX Limited Genetic Variation [31]
RBFOX1 OTFPKEL7 Limited Genetic Variation [31]
SFMBT1 OTKMZIBW Limited Genetic Variation [42]
SHLD2 OTMLERXL Limited Genetic Variation [45]
TPST1 OTDPQKEA Limited Genetic Variation [31]
A1CF OTJBKFA1 Strong Genetic Variation [38]
ALDH16A1 OT50NI6Z Strong Biomarker [47]
ALPK1 OTBW6SGD Strong Biomarker [48]
AP5B1 OTZGM9QA Strong Genetic Variation [38]
BABAM2 OTOY7FNT Strong Genetic Variation [38]
BAIAP2 OT1KKMYZ Strong Genetic Variation [49]
BAZ1B OTD5KR2J Strong Genetic Variation [38]
BCL7B OT8DQQRD Strong Genetic Variation [38]
CARMIL1 OT1A5IX5 Strong Genetic Variation [38]
CLNK OTOWK51S Strong Genetic Variation [38]
CRIP3 OT7H1YOY Strong Genetic Variation [38]
FBXO22 OTEJ5MO0 Strong Genetic Variation [38]
FNDC4 OTOQK0WK Strong Genetic Variation [38]
FRK OTEKV1SC Strong Genetic Variation [38]
GPN1 OTM03SFL Strong Genetic Variation [38]
GTF3C2 OTWDANLJ Strong Genetic Variation [38]
H1-2 OT0AVI4M Strong Genetic Variation [38]
H1-6 OTKY5UZ9 Strong Genetic Variation [38]
H2AC1 OTN5DENU Strong Genetic Variation [38]
H2AC4 OTMFQ662 Strong Genetic Variation [38]
H2AC6 OTF3YK7V Strong Genetic Variation [38]
H2BC1 OTNVTJAQ Strong Genetic Variation [38]
HFE OTDD93KB Strong Genetic Variation [38]
HLF OTTRK9XN Strong Genetic Variation [38]
HNF1B OTSYIC3T Strong Genetic Variation [50]
HNF4G OTTSIHJP Strong Genetic Variation [38]
IFT172 OT12DW08 Strong Genetic Variation [38]
INHBC OT8SUTZR Strong Genetic Variation [38]
INHBE OTOI2NYG Strong Genetic Variation [38]
KAT5 OTL7257A Strong Genetic Variation [38]
KRTCAP3 OTB24J5O Strong Genetic Variation [38]
MACROD1 OTWFEVRW Strong Genetic Variation [38]
MAPK6 OTDDNF3Q Strong Genetic Variation [49]
MEPE OTXJRUW0 Strong Genetic Variation [38]
MLXIP OT30UNI7 Strong Genetic Variation [38]
MLXIPL OTR9MLLW Strong Genetic Variation [38]
MPV17 OT579DMU Strong Genetic Variation [38]
MRPL33 OTA3YDH0 Strong Genetic Variation [38]
MT1B OTUA4FFH Strong Biomarker [51]
NALCN OTWY7DS0 Strong Genetic Variation [49]
NRBP1 OTRWEJ65 Strong Genetic Variation [38]
NUDT17 OTE8FOEW Strong Genetic Variation [38]
NXPH4 OTV057AG Strong Genetic Variation [38]
ORC4 OT3ACTST Strong Genetic Variation [38]
OVOL1 OTFJ62UI Strong Genetic Variation [38]
POLR3C OTPQX849 Strong Genetic Variation [38]
PPM1G OTLZL9CG Strong Genetic Variation [38]
PRKAG2 OTHTAM54 Strong Genetic Variation [38]
QRICH2 OTLSBRNF Strong Genetic Variation [38]
R3HDM2 OTMJ3S6J Strong Genetic Variation [38]
RAB27B OTPF9D0K Strong Genetic Variation [49]
RNASEH2C OTJL9ZRN Strong Genetic Variation [38]
RNF115 OT35B6L5 Strong Genetic Variation [38]
RREB1 OT62460U Strong Genetic Variation [38]
SCGN OTGD7SKH Strong Genetic Variation [38]
SLC4A1AP OTC5XRQM Strong Genetic Variation [38]
SNX17 OT2I652M Strong Genetic Variation [38]
TBL2 OTCIMSK8 Strong Genetic Variation [38]
TRIM38 OT6SP1M9 Strong Genetic Variation [38]
TRIM46 OTFE7WZW Strong Genetic Variation [38]
TRIM54 OTI49DD6 Strong Genetic Variation [38]
------------------------------------------------------------------------------------
⏷ Show the Full List of 81 DOT(s)

References

1 Allopurinol FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 Colchicine FDA Label
4 Indomethacin FDA Label
5 Naproxen FDA Label
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7463).
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4357).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5826).
9 ClinicalTrials.gov (NCT05007392) A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout. U.S.National Institutes of Health.
10 Specific binding of the new stable epoprostenol analogue beraprost sodium to prostacyclin receptors on human and rat platelets. Arzneimittelforschung. 1989 Apr;39(4):495-9.
11 ClinicalTrials.gov (NCT00353587) Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin. U.S. National Institutes of Health.
12 ClinicalTrials.gov (NCT04987242) An Inpatient, Placebo-Controlled Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects. U.S.National Institutes of Health.
13 ClinicalTrials.gov (NCT04155918) A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of AR882 Administered Alone or in Combination With Febuxostat or Allopurinol in Gout Patients. U.S.National Institutes of Health.
14 ClinicalTrials.gov (NCT01407874) A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency. U.S. National Institutes of Health.
15 ClinicalTrials.gov (NCT04130204) Randomized, Double-blinded, Placebo-controlled Study of the Efficacy and Safety of DYV700 for Reducing Pain Associated With an Acute Gout Flare. U.S.National Institutes of Health.
16 ClinicalTrials.gov (NCT01927198) RDEA3170 Monotherapy in Subjects With Gout. U.S. National Institutes of Health.
17 ClinicalTrials.gov (NCT05690204) A Phase 2B Study to Evaluate the Efficacy and Safety in Combination With Standard of Care in Adult Subjects With Gout, and Hyperuricemia Refractory to Conventional XOI Therapy. U.S.National Institutes of Health.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 ClinicalTrials.gov (NCT02327754) Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout. U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT02290210) Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT05256810) A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout. U.S.National Institutes of Health.
22 ClinicalTrials.gov (NCT01361646) Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189. U.S. National Institutes of Health.
23 Therapeutic potential of aleglitazar, a new dual PPAR-alpha/gamma agonist: implications for cardiovascular disease in patients with diabetes mellitus. Am J Cardiovasc Drugs. 2010;10(4):209-16.
24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018169)
25 ClinicalTrials.gov (NCT02187029) Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.. U.S. National Institutes of Health.
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000017)
27 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002649)
28 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010582)
29 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
30 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2646).
31 Gout and type 2 diabetes have a mutual inter-dependent effect on genetic risk factors and higher incidences.Rheumatology (Oxford). 2012 Apr;51(4):715-20. doi: 10.1093/rheumatology/ker373. Epub 2011 Dec 16.
32 Genome-Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol.Clin Pharmacol Ther. 2019 Sep;106(3):623-631. doi: 10.1002/cpt.1439. Epub 2019 May 23.
33 Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.Ann Rheum Dis. 2019 Oct;78(10):1430-1437. doi: 10.1136/annrheumdis-2019-215521. Epub 2019 Jul 8.
34 Decreased Expression of CD14 in MSU-Mediated Inflammation May Be Associated with Spontaneous Remission of Acute Gout.J Immunol Res. 2019 Jun 13;2019:7143241. doi: 10.1155/2019/7143241. eCollection 2019.
35 Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese.Nat Commun. 2015 May 13;6:7041. doi: 10.1038/ncomms8041.
36 Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.Ann Rheum Dis. 2016 Apr;75(4):652-9. doi: 10.1136/annrheumdis-2014-206191. Epub 2015 Feb 2.
37 Potential cow milk xanthine oxidase inhibitory and antioxidant activity of selected phenolic acid derivatives.J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22005. Epub 2017 Oct 26.
38 Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013 Feb;45(2):145-54. doi: 10.1038/ng.2500. Epub 2012 Dec 23.
39 Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008 May 2;320(5876):674-7. doi: 10.1126/science.1156995. Epub 2008 Apr 10.
40 The cyclic GMP-dependent protein kinase II gene associates with gout disease: identified by genome-wide analysis and case-control study.Ann Rheum Dis. 2009 Jul;68(7):1213-9. doi: 10.1136/ard.2008.093252. Epub 2008 Aug 4.
41 Amputation of the first metatarsophalangeal joint due to a giant gouty tophi: A case report.Medicine (Baltimore). 2017 Oct;96(43):e8441. doi: 10.1097/MD.0000000000008441.
42 Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.Nat Genet. 2019 Oct;51(10):1459-1474. doi: 10.1038/s41588-019-0504-x. Epub 2019 Oct 2.
43 HPRTSardinia: a new point mutation causing HPRT deficiency without Lesch-Nyhan disease.Biochim Biophys Acta. 2006 Jan;1762(1):29-33. doi: 10.1016/j.bbadis.2005.03.012. Epub 2005 Apr 13.
44 Multiplicative interaction of functional inflammasome genetic variants in determining the risk of gout.Arthritis Res Ther. 2015 Oct 13;17:288. doi: 10.1186/s13075-015-0802-3.
45 GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes.Ann Rheum Dis. 2017 May;76(5):869-877. doi: 10.1136/annrheumdis-2016-209632. Epub 2016 Nov 29.
46 Integrative Genome-Wide Association Studies of eQTL and GWAS Data for Gout Disease Susceptibility.Sci Rep. 2019 Mar 21;9(1):4981. doi: 10.1038/s41598-019-41434-4.
47 Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet. 2011 Oct 9;43(11):1127-30. doi: 10.1038/ng.972.
48 Enhanced alpha-kinase 1 accelerates multiple early nephropathies in streptozotocin-induced hyperglycemic mice. Biochim Biophys Acta. 2016 Nov;1862(11):2034-2042. doi: 10.1016/j.bbadis.2016.08.010. Epub 2016 Aug 16.
49 Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015 May;97(5):518-25.
50 Atypical familial juvenile hyperuricemic nephropathy associated with a hepatocyte nuclear factor-1beta gene mutation.Kidney Int. 2003 May;63(5):1645-51. doi: 10.1046/j.1523-1755.2003.00903.x.
51 Ultrasonographic detection of double contour sign and hyperechoic aggregates for diagnosis of gout: two sites examination is as good as six sites examination.Int J Rheum Dis. 2018 Feb;21(2):523-531. doi: 10.1111/1756-185X.13235. Epub 2017 Dec 5.